Radioactive Peptide Therapy Controls Rare Adrenal and Neural Tumors
Peptide receptor radionuclide therapy with 177Lu or 90Y peptides provided disease control in 30 patients with malignant pheochromocytomas and paragangliomas.
Quick Facts
What This Study Found
Peptide receptor radionuclide therapy with 177Lu or 90Y peptides provided disease control in patients with malignant pheochromocytomas and paragangliomas.
Key Numbers
30 patients identified from over 1,500 neuroendocrine tumor patients treated from 1999 to 2017. Treatment used 177Lu- or 90Y-DOTA-TATE or -TOC peptides.
How They Did This
Single-center retrospective analysis of 30 patients with malignant PCCs/PGLs treated with PRRT between 1999 and 2017, selected from over 1,500 neuroendocrine tumor patients.
Why This Research Matters
These rare tumors have very limited treatment options, especially when they have spread. Any therapy showing disease control provides hope for patients with few alternatives.
The Bigger Picture
Malignant pheochromocytomas and paragangliomas are rare tumors with very few effective treatments. Any therapy that controls disease progression provides meaningful benefit for patients with limited options.
What This Study Doesn't Tell Us
Retrospective single-center study with only 30 patients. No control group for comparison. Patient selection may have influenced outcomes.
Questions This Raises
- ?Which patients are most likely to respond to PRRT?
- ?Could combination with other therapies improve outcomes?
Trust & Context
- Key Stat:
- 30 patients from 1,500+ From over 1,500 neuroendocrine tumor patients, 30 with rare malignant pheochromocytomas/paragangliomas benefited from targeted peptide radiation therapy
- Evidence Grade:
- Rated moderate: 18-year single-center retrospective experience with 30 patients. Small numbers reflect the rarity of these tumors.
- Study Age:
- Published in 2024, covering 18 years of treatment experience (1999–2017). Provides the longest available follow-up for PRRT in this tumor type.
- Original Title:
- Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
- Published In:
- Endocrine, 84(2), 704-710 (2024)
- Authors:
- Rubino, Manila, Di Stasio, Giuseppe Danilo, Bodei, Lisa(2), Papi, Stefano, Rocca, Paola Anna, Ferrari, Mahila Esmeralda, Fodor, Cristiana Iuliana, Bagnardi, Vincenzo, Frassoni, Samuele, Mei, Riccardo, Fazio, Nicola, Ceci, Francesco, Grana, Chiara Maria
- Database ID:
- RPEP-09179
Evidence Hierarchy
Frequently Asked Questions
What is peptide receptor radionuclide therapy?
A treatment where radioactive atoms are attached to peptides that seek out and bind to tumor cells, delivering targeted radiation directly to the cancer.
What are pheochromocytomas and paragangliomas?
Rare tumors arising from adrenal glands or nerve tissue that produce excess hormones. When malignant, they have very few treatment options.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09179APA
Rubino, Manila; Di Stasio, Giuseppe Danilo; Bodei, Lisa; Papi, Stefano; Rocca, Paola Anna; Ferrari, Mahila Esmeralda; Fodor, Cristiana Iuliana; Bagnardi, Vincenzo; Frassoni, Samuele; Mei, Riccardo; Fazio, Nicola; Ceci, Francesco; Grana, Chiara Maria. (2024). Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.. Endocrine, 84(2), 704-710. https://doi.org/10.1007/s12020-024-03707-5
MLA
Rubino, Manila, et al. "Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.." Endocrine, 2024. https://doi.org/10.1007/s12020-024-03707-5
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor radionuclide therapy with 177Lu- or 90Y-SST..." RPEP-09179. Retrieved from https://rethinkpeptides.com/research/rubino-2024-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.